STARSTRUCK
14 Sep 2023
Trial Summary
This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.
Acronym:
STARSTRUCK
ACTRN/NCT /ethics:
NCT05868174
Scientific title:
Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors
Sponsor / Cooperative group:
Telix International Pty Ltd
Trial & Patient Characteristics
| Cancer Type | All |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2023-05-23 |
| Anticipated End Date | 2026-12-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre - Tennyson and Windsor Garden |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| Sue.Yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dainik Patel |
| Recruitment Status | Recruiting |